Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 16/20 | 0.58 |
| ▸ | TLR2 | O60603 | 1/20 | 0.58 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.58 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.44 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30989418 | 0.85 | ERN1 (0.58) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL17201123 | 0.85 | ERN1 (0.58) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL1527154 | 0.82 | ERN1 (0.69) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL2843121 | 0.82 | ALDH1A1 (0.50) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL3466295 | 0.79 | PRKDC (0.48) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL31195180 | 0.79 | PRKDC (0.48) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL8043039 | 0.79 | ERN1 (0.59) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL1620491 | 0.79 | ALDH1A1 (0.47) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL13605931 | 0.79 | ERN1 (0.59) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL15195939 | 0.79 | ALDH1A1 (0.47) | ERN1TLR2TLR1TLR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245367-A1 | INHIBITING CATECHOL-O-METHYLTRANSFERASE (COMT) | PSY THERAPEUTICS, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | LILLY CO ELI (US) | 2025-11-20 | — | — | US | disclosed |
| US-12404298-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240300962-A1 | Isoquinoline Derivatives, Methods of Synthesis and Uses Thereof | PROSETTA BIOSCIENCES INC (US) | 2024-09-12 | — | — | US | disclosed |
| US-12024521-B2 | Isoquinoline derivatives, methods of synthesis and uses thereof | PROSETTA BIOSCIENCES, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024521-B2 | Isoquinoline derivatives, methods of synthesis and uses thereof | PROSETTA BIOSCIENCES, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024521-B2 | Isoquinoline derivatives, methods of synthesis and uses thereof | PROSETTA BIOSCIENCES, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240130988-A1 | Use of stilbene compounds in the preparation of anti-tumor drugs | GUANGZHOU ANHAO PHARMACEUTICAL TECHNOLOGY CO LTD. (CN) | 2024-04-25 | — | — | US | disclosed |
| EP-4342463-A1 | STILBENE COMPOUNDS FOR USE IN THE TREATMENT OF TUMOUR AND EYE DISEASES | Guangzhou AnHao Pharmaceutical Technology Co., Ltd. (CN) | 2024-03-27 | — | — | EP | disclosed |
| US-20240018182-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2024-01-18 | — | — | US | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
| EP-1421061-A1 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | Incyte San Diego Incorporated (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20030153606-A1 | Thiazolidinedione derivatives for the treatment of diabetes and other diseases | MAXIA PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2003016267-A1 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | INCYTE SAN DIEGO INCORPORATED (US) | 2003-02-27 | — | — | WO | disclosed |
| US-6515003-B1 | Useful in the treatment of diseases related to lipid and carbohydrate metabolism | MAXIA PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| CN-1384825-A | Benzylidene-thiazolidinediones and analogues thereof and their use in the treatment of diabetes | MAXIA PHARMACEUTICALS INC (US) | 2002-12-11 | — | — | CN | disclosed |
| EP-1214304-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001016122-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240130988-A1 | Use of stilbene compounds in the preparation of anti-tumor drugs | CD4, CD81, NFATC1 | ERN1 3768/4885TLR2 55/4885TLR1 77/4885 |
| US-12024521-B2 | Isoquinoline derivatives, methods of synthesis and uses thereof | POLRMT, MAVS, SYNCRIP | ERN1 1096/4885TLR2 3214/4885TLR1 2781/4885 |
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | ERN1 1226/4885TLR2 2690/4885TLR1 485/4885 |
| US-12404298-B2 | Glucocorticoid receptor agonists | NR3C1, NR3C2, MC2R | ERN1 1650/4885TLR2 156/4885TLR1 145/4885 |
| US-20240018182-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | ERN1 1650/4885TLR2 156/4885TLR1 145/4885 |
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | ERN1 1650/4885TLR2 156/4885TLR1 145/4885 |
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | OAT, CPT1A, CYP27A1 | ERN1 1162/4885TLR2 1569/4885TLR1 1160/4885 |
| US-20240300962-A1 | Isoquinoline Derivatives, Methods of Synthesis and Uses Thereof | POLRMT, MAVS, SYNCRIP | ERN1 1096/4885TLR2 3214/4885TLR1 2781/4885 |
| US-20030153606-A1 | Thiazolidinedione derivatives for the treatment of diabetes and other diseases | FABP4, PPARG, CPT2 | ERN1 4373/4885TLR2 38/4885TLR1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.